| Literature DB >> 26308881 |
Mallory R Gordon1, Mine Canakci1, Longyu Li1, Jiaming Zhuang1, Barbara Osborne1, S Thayumanavan1.
Abstract
Antibody-drug conjugates have attracted a great amount of attention as a therapeutic strategy for diseases where targeting specific tissues and cells are critical components, such as in cancer therapy. Although promising, the number of approved ADC drugs is relatively limited. This emanates from the challenges associated with generating the conjugates and the complexities associated with the stability requirements for these conjugates during circulation and after reaching the target. Here, we provide a comprehensive overview of the design challenges facing the ADC field. These challenges also provide several unique research and development opportunities, which are also highlighted throughout the review.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26308881 PMCID: PMC4933296 DOI: 10.1021/acs.bioconjchem.5b00399
Source DB: PubMed Journal: Bioconjug Chem ISSN: 1043-1802 Impact factor: 4.774